TGFB1 and cancer: Besides TGF‐β and PD‐1 signaling pathways, other immunoinhibitory factors in the TME also participate in cancer immune evasion and contribute to immunotherapy resistance.[48, 49] Therefore, exploring changes in the TME composition is meaningful to maximize YM101 efficacy and reduce the risk of treatment resistance.